Key Players
Competitive Landscape
Four supplier models compete in the giant cell arteritis market: originator biologic groups, oral immunology developers, biosimilar manufacturers and commercial rights holders.
Commercial activity has moved in two directions since 2025: oral steroid-sparing access and wider tocilizumab biosimilar supply. AbbVie secured European Commission approval for Rinvoq in April 2025. Celltrion received USA approval for intravenous and subcutaneous AVTOZMA in January 2025. Price remains relevant, although hospital committees and payers first compare remission evidence against administration route and reimbursed access.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| AbbVie secured European Commission approval for oral Rinvoq in April 2025. | Specialists need a steroid-sparing oral route for eligible adults. | Competition now extends beyond injectable interleukin-6 therapy. | Revenue depends on safety screening and payer placement for oral treatment. |
| Celltrion received USA approval for intravenous and subcutaneous AVTOZMA in January 2025. | Health systems need lower-cost options across infusion and self-injection. | Biosimilar competition now covers hospital and outpatient routes. | Revenue spans formulary contracts, specialty pharmacy dispensing and patient support. |
| Organon acquired USA TOFIDENCE rights from Biogen in April 2025. | Hospital channels need an approved intravenous tocilizumab alternative. | Commercial control is shifting from developers toward dedicated biosimilar marketers. | Revenue is available through hospital contracts and reimbursed infusion supply. |
Roche, Fresenius Kabi and Bio-Thera compete on indication history, route coverage and manufacturing rights. No qualifying 2025-2026 exact-market development was identified for these three companies.
Source: Future Market Insights, Giant Cell Arteritis Market and Biosimilars and Follow-on Biologics Market Reports, 2026-2036.
Roche and AbbVie cover approved biologic and oral routes, while biosimilar groups extend regional supply and Novartis contributes completed phase III evidence.
Who leads the giant cell arteritis market?
F. Hoffmann-La Roche Ltd. leads on length of approved GCA use after Actemra gained USA approval in May 2017. AbbVie Inc. holds the first approved oral JAK inhibitor route following the April 2025 European Commission approval of Rinvoq.
Which suppliers hold documented giant cell arteritis marketing approvals?
Roche, AbbVie, Fresenius Kabi, Celltrion, Organon and Gedeon Richter supply medicines with documented giant cell arteritis approvals in one or more major regions. Bio-Thera retains TOFIDENCE manufacturing rights, while Novartis has completed phase III evidence without an approved GCA indication.
Which companies provide injectable or oral steroid-sparing products?
Roche supplies originator tocilizumab through subcutaneous and intravenous routes. Fresenius Kabi, Celltrion, Organon and Gedeon Richter supply approved tocilizumab biosimilars, while AbbVie supplies oral upadacitinib.
Which suppliers serve North America and Europe?
Roche, AbbVie, Fresenius Kabi and Celltrion serve both regions through approved products or commercial rights. Organon focuses on the United States, Gedeon Richter serves Europe, Bio-Thera retains USA manufacturing rights and Novartis has a global clinical-development footprint.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| F. Hoffmann-La Roche Ltd. | Global | Originator tocilizumab for adult giant cell arteritis with subcutaneous and intravenous routes. |
| AbbVie Inc. | Global | Oral upadacitinib for adult giant cell arteritis with USA and European approvals in April 2025. |
| Fresenius Kabi AG | North America and Europe | Tyenne tocilizumab biosimilar with intravenous and subcutaneous routes with USA reimbursement coding. |
| Celltrion Inc. | North America, Europe and Asia | AVTOZMA tocilizumab biosimilar with intravenous and subcutaneous formulations with USA commercial availability. |
| Organon & Co. | United States | TOFIDENCE intravenous tocilizumab biosimilar with USA commercial rights acquired in April 2025. |
| Gedeon Richter Plc. | Europe | Tuyory tocilizumab biosimilar with intravenous and subcutaneous routes authorized in April 2026. |
| Bio-Thera Solutions, Ltd. | United States manufacturing | TOFIDENCE developer and retained USA manufacturing-rights holder under the Organon transaction. |
| Novartis AG | Global clinical development | Secukinumab GCAptAIN phase III program with the primary endpoint missed in July 2025. |
Research Methodology
The companies show how giant cell arteritis competition is structured and do not form a ranking. A company appears where current evidence confirms an approved medicine, an exact-market development program or a commercial right relevant to treatment. Evidence includes regulator records, company filings, official announcements and current trial disclosures. Approvals belong to the legal entity or regional rights holder named by each source. The 49.0% biologic therapy share remains an FMI estimate for 2026.
